Yaakov Nahmias is a groundbreaking biotechnology brand known as Tissue Dynamics Ltd. They specialize in the development and provision of advanced toxicology screening services for the pharmaceutical and cosmetics industries. Tissue Dynamics offers next-generation organ-on-chip technology, which consists of bionic microtissues embedded with electrooptical sensors.

These sensors provide critical insight into human-relevant mechanisms. Powered by unprecedented AI and automation capabilities, these proprietary models offer physiological insights for drug discovery. One of Tissue Dynamics' main goals is to disrupt the drug development landscape by dramatically increasing clinical success rates using human-relevant models and sensor-driven discovery.

By providing data-driven insights on mechanisms of action, their models reduce clinical risk and offer crucial information on human-specific efficacy, possible adverse events, dose, distribution, and drug target interactions. This approach can reduce drug development costs by up to 80%. Tissue Dynamics has also made significant contributions in fighting the global COVID-19 pandemic.

Their team, led by Professor Yaakov Nahmias, discovered fenofibrate as a treatment for lipotoxicity caused by viral infection, uncovering human-specific interventions that were previously unavailable in small animal models. If you're interested in learning more about Tissue Dynamics and how they can benefit your business, don't hesitate to contact them. Their headquarters are located at 10 Prof.

Menakhem Plaut St., Rehovot, 7670609, Israel